Abiopharma

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

EDAP Reports Third Quarter 2025 Financial Results

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

NeoGenomics to Participate in Upcoming Investor Conferences